NASDAQ:BDSI - BioDelivery Sciences International Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.90 -0.10 (-3.33 %)
(As of 07/16/2018 06:00 AM ET)
Previous Close$2.90
Today's Range$2.85 - $3.00
52-Week Range$1.70 - $3.60
Volume119,992 shs
Average Volume439,467 shs
Market Capitalization$172.12 million
P/E RatioN/A
Dividend YieldN/A
BioDelivery Sciences International logoBioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. has a licensing and development agreement with Evonik Corporation and Meda AB. The company was founded in 1997 and is headquartered in Raleigh, North Carolina.

Receive BDSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BDSI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio35.82
Current Ratio1.40
Quick Ratio1.13


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$61.99 million
Price / Sales2.78
Cash FlowN/A
Price / CashN/A
Book Value$0.16 per share
Price / Book18.13


EPS (Most Recent Fiscal Year)($0.39)
Net Income$5.28 million
Net Margins-122.75%
Return on Equity-388.58%
Return on Assets-61.59%


Outstanding Shares59,350,000
Market Cap$172.12

The Truth About Cryptocurrencies

BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions

What is BioDelivery Sciences International's stock symbol?

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

How were BioDelivery Sciences International's earnings last quarter?

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) issued its earnings results on Thursday, May, 10th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.03. The specialty pharmaceutical company had revenue of $11.28 million for the quarter, compared to analysts' expectations of $10.77 million. BioDelivery Sciences International had a negative return on equity of 388.58% and a negative net margin of 122.75%. View BioDelivery Sciences International's Earnings History.

When is BioDelivery Sciences International's next earnings date?

BioDelivery Sciences International is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for BioDelivery Sciences International.

What price target have analysts set for BDSI?

6 equities research analysts have issued 1 year target prices for BioDelivery Sciences International's shares. Their predictions range from $4.00 to $5.00. On average, they expect BioDelivery Sciences International's share price to reach $4.3333 in the next year. This suggests a possible upside of 49.4% from the stock's current price. View Analyst Ratings for BioDelivery Sciences International.

What is the consensus analysts' recommendation for BioDelivery Sciences International?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioDelivery Sciences International in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about BioDelivery Sciences International stock?

Here are some recent quotes from research analysts about BioDelivery Sciences International stock:
  • 1. HC Wainwright analysts commented, "Valuation and risks. We assume Belbuca continues to grow rapidly to $125M by 2022 (approximately $150M peak), with BDSI cash- flow positive in 2020, and fully profitable by 2021. Our $3.50 12- month price target is based on a DCF with an 11% WACC discount, and negative -15% terminal growth beyond 2027." (7/6/2018)
  • 2. Cantor Fitzgerald analysts commented, "Positives from the quarter: 1) BDSI announced it had secured preferred coverage for Belbuca with Humana (HUM, Neutral) effective March 1. Effective Jan. 1, 2018, United Healthcare (UNH, OW) removed step edits for Belbuca, and CVS/Caremark (CVS, Not covered) and ProCareRx moved Belbuca to a preferred position. Additionally, Belbuca and Butrans have been added to the Ohio Workers Comp formulary as preferred medications, effective 4/1/18; 2) Belbuca prescriptions grew 10% in 4Q17 vs. 3Q17, and have continued to grow in 2018; 3) Scott Plesha was appointed to the role of President; and 4) cash and equivalents totaled $21.9MM at 12/31/17, which should fund operations into 2H18. Management noted on the call that it could potentially qualify for an additional tranche of its loan agreement in 2018. Other levers the company has to decrease cash burn and extend the cash runway include better-than- expected sales, lower R&D and SG&A spending, and potential partnerships or divestments of the company’s other products." (3/15/2018)
  • 3. According to Zacks Investment Research, "BioDelivery has secured improved positioning in six new managed care contracts providing preferred access to its key drug, Bunavail, since July 2016. This is expected to boost the drug’s sales and profitability in turn. Meanwhile, its second marketed drug, Belbuca, recently received an approval in Canada for severe pain that should support further sales growth. BioDelivery’s shares have significantly outperformed the industry in the last one year. However, the company suffered a setback with the discontinuation of clonidine topical gel for management of painful diabetic neuropathy in December 2016. BioDelivery’s portfolio as well as its pipeline candidates may also face a severe competition as it targets a highly genericized and crowded market." (2/14/2018)

Who are some of BioDelivery Sciences International's key competitors?

Who are BioDelivery Sciences International's key executives?

BioDelivery Sciences International's management team includes the folowing people:
  • Mr. Ernest Robert De Paolantonio, CFO, Corp. Sec. & Treasurer (Age 65)
  • Mr. Herm Cukier, Principal Exec. Officer, CEO & Director
  • Mr. Scott M. Plesha, Pres (Age 53)
  • Mr. Joseph M. Lockhart, Sr. VP of Operations
  • Mr. James D. Darnley Jr., VP, Gen. Counsel & Commercial Compliance Officer

Has BioDelivery Sciences International been receiving favorable news coverage?

Media coverage about BDSI stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BioDelivery Sciences International earned a coverage optimism score of 0.10 on Accern's scale. They also assigned media headlines about the specialty pharmaceutical company an impact score of 43.26 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are BioDelivery Sciences International's major shareholders?

BioDelivery Sciences International's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BROADFIN CAPITAL, LLC (7.30%) and BROADFIN CAPITAL, LLC (7.30%). Company insiders that own BioDelivery Sciences International stock include Barry I Feinberg, Francis E Odonnell Jr, Mark A Sirgo, Niraj Vasisht, Paolantonio Ernest Robert De, Samuel P Sears, Jr and William B Stone. View Institutional Ownership Trends for BioDelivery Sciences International.

How do I buy shares of BioDelivery Sciences International?

Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioDelivery Sciences International's stock price today?

One share of BDSI stock can currently be purchased for approximately $2.90.

How big of a company is BioDelivery Sciences International?

BioDelivery Sciences International has a market capitalization of $172.12 million and generates $61.99 million in revenue each year. The specialty pharmaceutical company earns $5.28 million in net income (profit) each year or ($0.39) on an earnings per share basis. BioDelivery Sciences International employs 116 workers across the globe.

How can I contact BioDelivery Sciences International?

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]

MarketBeat Community Rating for BioDelivery Sciences International (NASDAQ BDSI)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  386 (Vote Outperform)
Underperform Votes:  196 (Vote Underperform)
Total Votes:  582
MarketBeat's community ratings are surveys of what our community members think about BioDelivery Sciences International and other stocks. Vote "Outperform" if you believe BDSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.